首页> Journal of medicinal chemistry> Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M<sub>4</sub> Muscarinic Acetylcholine Receptor.

Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M<sub>4</sub> Muscarinic Acetylcholine Receptor.

导出 LinkOut

翻译打印收藏纠错

第一作者： Christopher R,Butler

第一单位： Medicine Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States.

作者： Christopher R,Butler ^[1] ; Michael,Popiolek ^[2] ; Laura A,McAllister ^[1] ; Erik A,LaChapelle ^[3] ; Melissa,Kramer ^[4] ; Elizabeth M,Beck ^[1] ; Scot,Mente ^[1] ; Michael A,Brodney ^[1] ; Matthew,Brown ^[3] ; Adam,Gilbert ^[3] ; Chris,Helal ^[3] ; Kevin,Ogilvie ^[3] ; Jeremy,Starr ^[3] ; Daniel,Uccello ^[3] ; Sarah,Grimwood ^[2] ; Jeremy,Edgerton ^[2] ; Jonathan,Garst-Orozco ^[2] ; Rouba,Kozak ^[2] ; Susan,Lotarski ^[2] ; Amie,Rossi ^[2] ; Deborah,Smith ^[2] ; Rebecca,O'Connor ^[5] ; John,Lazzaro ^[5] ; Claire,Steppan ^[5] ; Stefanus J,Steyn ^[4]

作者单位： Medicine Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States. ^[1] Internal Medicine, Pfizer Inc., Cambridge, Massachusetts 02139, United States. ^[2] Medicine Design, Medicinal Chemistry, Pfizer Inc., Groton, Connecticut 06340, United States. ^[3] Medicine Design, Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, Connecticut 06340, United States. ^[4] Discovery Sciences, Primary Pharmacology, Pfizer Inc., Groton, Connecticut 06340, United States. ^[5]